E66: Newtropics, ChatGPT for Enterprise, Democratizing Music, and Catching Kidney Disease

Our Social Media Pages, follow us and engage with the Pill-grim community!Join our Entre CommunityInstagramTwitter YouTubeTikTokLinkedInAnd now, for this week’s prescription:On this week’s dose, (2:27) we start things off with a discussion on Thesis, a startup that offers personalized nootropic formulas to enhance performance based on brain chemistry, and its recent $13.5M funding round. (8:03) Next, we talk about Cohere, an AI company that’s creating a ChatGPT-type product geared toward privacy-prioritizing enterprises, and its massive $250M raise. (14:05) From there, we breakdown Duetti’s $32M raise, and how the startup is getting in on the music catalog sales market by providing funding to independent, rising artists in exchange for their music. (19:27) Lastly, we wrap up this week’s dose with a discourse on Healthy.io, a startup that’s developing game-changing technology that will help millions of people detect Chronic Kidney Disease using a smartphone, fresh off its $50M Series D.Sources:https://www.finsmes.com/2023/05/thesis-raises-13-5m-in-funding.htmlhttps://takethesis.com/https://cohere.com/about https://www.ft.com/content/84bfc44e-d1f3-4b83-9986-ed0d958b5f4c https://duetti.co/https://www.billboard.com/pro/tidal-apple-execs-music-financing-firm-indie-artists/https://healthy.io/about-us/ https://www.investorsobserver.com/news/qm-pr/7668628238261655 https://www.axios.com/pro/health-tech-deals/2023/05/03/healthyio-raises-50-m-series-d-smartphone-testing-kidney-disease-ckd-woundsMusic Credit: Chapter One by Cole Bauer and Dean Keetonhttps://www.colebauer.com/https://www.instagram.com/deankeeton/?hl=enDisclosure:The views, statements, and opinions,  expressed herein by the hosts and guests are their own, and their appearance on the podcast should not be construed as reflecting the views or implied endorsement of Independent Brokerage Solutions LLC or any of its officers, employees, or agents. The statements made herein should not be considered an investment opinion, advice, or a recommendation regarding securities of any company. This podcast is produced solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy a security.